Navigation Links
Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
Date:6/16/2008

ny dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's website at http://www.exelixis.com.

Disclaimer

Participation by Dr. Ball and Dr. Nelkin in the development of this product as members of the Clinical Steering Committee does not constitute endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation statements related to: the timing of the initiation and size of clinical trials for XL184; the future development and potential efficacy of XL184; and our strategy to advance compounds and expand into broader commercial markets. Words such as "plan," "expect," "will," "may" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current plans, assumptions, beliefs and expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the potential failure of XL184 and our other compounds to demonstrate safety and efficacy in clinical
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
2. Exelixis Receives $150 Million Funding Commitment From Deerfield Management
3. Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
4. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
5. REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
6. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
7. Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
8. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
9. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
11. Option to Develop Exelixis Compound Exercised By Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
(Date:10/20/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to $5.8 million and provides a good start to Q4.  The ... America and one in the Middle East ... record levels," said Peter Bruijns , President & CEO. "Total ... Q3 than they have been for any complete year since the ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy is seeking ... stem cells for dogs with osteoarthritis. Dr. McCarthy has ... clinical stem cell therapy for 7 years. The ultimate ... single injection of donor stem cells into one or ... inflammation in the treated joints. , Candidates for ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... venture capital in more deals in 2006, but the improvement ... Ernst & Young, LLP and Dow Jones ... in 2006, including a $12 .5 million round by ... for a total of $58.47 million. The total, up from ...
... Lance Armstrong is a unique phenomenon. He's a talented athlete, ... league by himself. Or is he? , ,As many people know, ... National Center for Health Statistics report released by the ... the second year in a row. , ,Cancer patients as political ...
... director of technology programs for the University of Wisconsin-Madison, is ... he demonstrates in Part II of this interview. In ... In Part II (below), he addresses creating a culture of ... also is a featured speaker at the Fusion 2007 ...
Cached Biology Technology:Wisconsin fares slightly better in venture capital chase 2Wisconsin fares slightly better in venture capital chase 3Lance Armstrong and the future of cancer care 2Lance Armstrong and the future of cancer care 3Lance Armstrong and the future of cancer care 4Lance Armstrong and the future of cancer care 5
(Date:10/14/2014)... JOLLA, CA – October 14, 2014 – Scientists from ... million from the National Institutes of Health (NIH) to ... prevalent virus-induced hemorrhagic fever disease in Africa. The study ... and why some patients die, while others survive the ... to understand the basic mechanism of how Lassa fever ...
(Date:10/14/2014)... team of researchers, led by the Chinese Academy of ... Nature Genetics a brief genomic history of tomato ... tomato plant. , The C.M. Rick Tomato Genetics Resource ... this study by providing seed of both cultivated tomato ... builds on the first tomato genome sequence completed just ...
(Date:10/14/2014)... October 14, 2014 – Over the past decades, we ... institutions to meet the needs of infants for social ... these infants to thrive. , Infancy and ... of the cortex. A generation of research suggests that ... cortical development and cognitive function. In contrast, deprivation and ...
Breaking Biology News(10 mins):Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2Institutional rearing may increase risk attention-deficit disorder 2
... that links global warming to the recent extinction of ... evidence of a large phenomena that may affect broad ... researchers at Oregon State University. , A study being ... that global climate change created favorable conditions for a ...
... Assertive and even aggressive human behavior could explain why ... downward trend in close encounters with the oceanic predators, ... precautions and in-your-face responses to confrontations with sharks went ... attacks from 65 in 2004 to 58 in 2005 ...
... Very thin but hardy, unblemished skin and slow developing ... hatched Antarctic notothenioids, a group of fish whose adults ... in their blood. , Such adaptations are important, researchers ... larval fish of at least two species of notothenioids ...
Cached Biology News:Extinctions linked to climate change 2Extinctions linked to climate change 3World shark attacks dipped in 2005, part of long-term trend 2World shark attacks dipped in 2005, part of long-term trend 3Thin tough skin, slow-growing gills protect larval Antarctic fish 2Thin tough skin, slow-growing gills protect larval Antarctic fish 3
... demands of the routine trace metal analytical ... robust and simple to use instrumentation. The ... most challenging sample matrices found in the ... the toughest analytical challenges found in the ...
... Do you need to make your strain ... efficiency? Take advantage of Lucigen’s unrivalled expertise ... Competent Cell Service offers: Chemically ... efficiencies Fast turnaround ...
Procollagen type I C-terminal propeptide (human, PICP)...
... in Microarrays: Biomedical Photometrics Inc. (Waterloo, Ontario, ... Germany) have collaborated to develop a fluorescence ... The DNAscope AT is based on ... AT automatically reads up to six ArrayTubes ...
Biology Products: